Skip to content

INNOVUS PHARMACEUTICALS, INC.: 10-Q filed 2016-08-15

What INNOVUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-08-15 (fiscal Q2 2016): 32 published measures, 81 facts as tagged in accession 0001415889-16-006852.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-15
Fiscal period
fiscal Q2 2016
Accession
0001415889-16-006852 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INNOVUS PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-308,001,266USD
At 2015-12-316,347,005USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-06-308,179,464USD
At 2015-12-316,793,343USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-30-178,198USD
At 2015-12-31-446,338USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-302,300,000USD
At 2015-12-31200,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-4,360,340USD91
2016-01-01 to 2016-06-30-5,915,309USD182
2015-04-01 to 2015-06-30-864,273USD91
2015-01-01 to 2015-06-30-2,366,031USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-01-01 to 2016-06-30256,152USD182
2015-01-01 to 2015-06-30-128,361USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-06-306,565USD182
2015-01-01 to 2015-06-309,537USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,019,520USD91
2016-01-01 to 2016-06-301,244,983USD182
2015-04-01 to 2015-06-30183,473USD91
2015-01-01 to 2015-06-30380,325USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-107,355USD182
2015-01-01 to 2015-06-30150,113USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-6,565USD182
2015-01-01 to 2015-06-30-12,814USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-21,349,904USD
At 2015-12-31-15,434,595USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-06-3034,296USD
At 2015-12-3135,101USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-442,393USD91
2016-01-01 to 2016-06-30-1,660,286USD182
2015-04-01 to 2015-06-30-782,524USD91
2015-01-01 to 2015-06-30-2,110,094USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-301,785,531USD
At 2015-12-31446,719USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,877,149USD91
2016-01-01 to 2016-06-302,273,584USD182
2015-04-01 to 2015-06-3097,484USD91
2015-01-01 to 2015-06-30271,366USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-303,812,035USD
At 2015-12-312,631,611USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2016-06-30549,368USD
At 2015-12-31549,368USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-06-305,580,000USD
At 2015-12-315,300,859USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-06-3022,147USD
At 2015-12-3183,097USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,461,913USD91
2016-01-01 to 2016-06-302,905,269USD182
2015-04-01 to 2015-06-30965,997USD91
2015-01-01 to 2015-06-302,490,419USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-06-30222,437USD
At 2015-12-31254,443USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-303,892USD91
2016-01-01 to 2016-06-303,892USD182
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-3087,176,763shares
At 2015-12-3147,141,230shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-3020,611,715USD
At 2015-12-3114,941,116USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2016-06-30570,540USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2016-06-305,579,653USD
At 2015-12-315,300,859USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,195,087USD91
2016-01-01 to 2016-06-302,518,320USD182
2015-04-01 to 2015-06-30901,968USD91
2015-01-01 to 2015-06-302,349,970USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-01-01 to 2016-06-307,370USD182
2015-01-01 to 2015-06-3017,815USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-04-01 to 2016-06-30178,083USD91
2016-01-01 to 2016-06-30335,685USD182
2015-04-01 to 2015-06-30147,236USD91
2015-01-01 to 2015-06-30239,582USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-3,917,947USD91
2016-01-01 to 2016-06-30-4,255,023USD182
2015-04-01 to 2015-06-30-81,749USD91
2015-01-01 to 2015-06-30-255,937USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-3055,242USD182
2015-01-01 to 2015-06-30153,716USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-3032,006USD182
2015-01-01 to 2015-06-30-25,130USD181

Inspect the source

Entity
INNOVUS PHARMACEUTICALS, INC. / CIK 0001411879
Captured
SEC response SHA-256
e77a101a672b8634c33f41442578c32e719835a043b28e20b379158f9e2f8bab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411879.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))